Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
Dose-response
Functioning
Major depressive disorder (MDD)
Real-world effectiveness
Vortioxetine
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
12 08 2022
12 08 2022
Historique:
received:
16
11
2021
accepted:
29
06
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
17
8
2022
Statut:
epublish
Résumé
Functional recovery is an important treatment goal in major depressive disorder (MDD). This study assessed the real-world effectiveness of vortioxetine in patients with MDD, with particular focus on functioning; dose-response was also assessed. This was a non-interventional, prospective, multicenter study conducted in Greece. Adult outpatients with MDD (n = 336) initiating vortioxetine (5-20 mg/day flexible dosing) as treatment for a current major depressive episode were followed for 3 months. Analyses were stratified according to vortioxetine dosage at 3 months: 5-10 mg/day versus 15-20 mg/day. Functioning was assessed using the Sheehan Disability Scale (SDS). Mean ± standard error SDS total score decreased (improved) from 18.7 ± 0.3 at baseline to 12.9 ± 0.3 after 1 month of vortioxetine treatment and 7.8 ± 0.4 after 3 months (p < 0.001 vs. baseline for all comparisons). Functional recovery (SDS score ≤ 6) was achieved in 14.6% of patients after 1 month of treatment and 48.4% of patients after 3 months. Improvement from baseline in SDS total and domain scores at 3 months was more pronounced in patients receiving vortioxetine 15-20 mg/day than in those receiving vortioxetine 5-10 mg/day. The mean ± standard error change in SDS total score from baseline was 9.2 ± 0.8 in the 5-10 mg/day group and 12.1 ± 0.4 in the 15-20 mg/day group (p < 0.001). Limitations of this study include its non-interventional study design and lack of a control group or active comparator. Statistically significant and clinically relevant improvements in functioning were seen in patients with MDD treated with vortioxetine in a real-world setting. Higher doses of vortioxetine were associated with significantly greater improvements in functioning.
Sections du résumé
BACKGROUND
Functional recovery is an important treatment goal in major depressive disorder (MDD). This study assessed the real-world effectiveness of vortioxetine in patients with MDD, with particular focus on functioning; dose-response was also assessed.
METHODS
This was a non-interventional, prospective, multicenter study conducted in Greece. Adult outpatients with MDD (n = 336) initiating vortioxetine (5-20 mg/day flexible dosing) as treatment for a current major depressive episode were followed for 3 months. Analyses were stratified according to vortioxetine dosage at 3 months: 5-10 mg/day versus 15-20 mg/day. Functioning was assessed using the Sheehan Disability Scale (SDS).
RESULTS
Mean ± standard error SDS total score decreased (improved) from 18.7 ± 0.3 at baseline to 12.9 ± 0.3 after 1 month of vortioxetine treatment and 7.8 ± 0.4 after 3 months (p < 0.001 vs. baseline for all comparisons). Functional recovery (SDS score ≤ 6) was achieved in 14.6% of patients after 1 month of treatment and 48.4% of patients after 3 months. Improvement from baseline in SDS total and domain scores at 3 months was more pronounced in patients receiving vortioxetine 15-20 mg/day than in those receiving vortioxetine 5-10 mg/day. The mean ± standard error change in SDS total score from baseline was 9.2 ± 0.8 in the 5-10 mg/day group and 12.1 ± 0.4 in the 15-20 mg/day group (p < 0.001). Limitations of this study include its non-interventional study design and lack of a control group or active comparator.
CONCLUSIONS
Statistically significant and clinically relevant improvements in functioning were seen in patients with MDD treated with vortioxetine in a real-world setting. Higher doses of vortioxetine were associated with significantly greater improvements in functioning.
Identifiants
pubmed: 35962369
doi: 10.1186/s12888-022-04109-5
pii: 10.1186/s12888-022-04109-5
pmc: PMC9373318
doi:
Substances chimiques
Vortioxetine
3O2K1S3WQV
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
548Informations de copyright
© 2022. The Author(s).
Références
CNS Spectr. 2016 Feb;21(1):43-52
pubmed: 24067243
Int Clin Psychopharmacol. 2011 Mar;26(2):75-83
pubmed: 21102344
Int J Neuropsychopharmacol. 2014 Oct;17(10):1557-67
pubmed: 24787143
Neuropsychiatr Dis Treat. 2019 Aug 13;15:2313-2323
pubmed: 31616147
Int J Neuropsychopharmacol. 2018 Feb 1;21(2):128-144
pubmed: 29024974
Front Psychiatry. 2019 Jan 31;10:17
pubmed: 30766492
Clin Pharmacokinet. 2018 Jun;57(6):673-686
pubmed: 29189941
Eur Neuropsychopharmacol. 2016 Jun;26(6):979-93
pubmed: 27139079
Acta Psychiatr Scand. 2020 Dec;142(6):430-442
pubmed: 32970827
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
Int J Neuropsychopharmacol. 2016 Jun 15;19(10):
pubmed: 27312740
Acta Psychiatr Scand. 2021 May;143(5):434-443
pubmed: 33404081
Prim Care Companion CNS Disord. 2016 Sep 01;18(5):
pubmed: 27835721
Neuropsychiatr Dis Treat. 2018 Oct 29;14:2861-2877
pubmed: 30464471
CNS Spectr. 2019 Dec;24(6):616-627
pubmed: 30802419
Clin Ther. 2003 Aug;25(8):2289-304
pubmed: 14512135
Can J Psychiatry. 2016 Sep;61(9):510-23
pubmed: 27486151
CNS Spectr. 2019 Jun;24(3):338-347
pubmed: 29792585
Neuropsychiatr Dis Treat. 2018 Jan 09;14:239-249
pubmed: 29386897
Br J Psychiatry. 1986 May;148:599-601
pubmed: 3779233
Hum Psychopharmacol. 2014 Sep;29(5):470-82
pubmed: 25087600
Transl Psychiatry. 2016 Jun 07;6(6):e834
pubmed: 27271860
Int Clin Psychopharmacol. 2008 Mar;23(2):70-83
pubmed: 18301121
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Pharmacol Ther. 2015 Jan;145:43-57
pubmed: 25016186
J Affect Disord. 2013 Oct;151(1):59-65
pubmed: 23790554
J Psychopharmacol. 2016 Mar;30(3):242-52
pubmed: 26864543
J Affect Disord. 2018 Mar 15;229:421-428
pubmed: 29331703
J Affect Disord. 2021 Mar 15;283:472-479
pubmed: 33516560
J Affect Disord. 2018 Feb;227:803-809
pubmed: 29673132
Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:89-95
pubmed: 8923116
Neuropsychiatr Dis Treat. 2021 Feb 22;17:575-585
pubmed: 33654400
Front Psychiatry. 2022 Mar 09;13:824831
pubmed: 35356713
Neuropsychopharmacology. 2015 Jul;40(8):2025-37
pubmed: 25687662
Brain Behav. 2017 Feb 02;7(3):e00622
pubmed: 28293465
Dialogues Clin Neurosci. 2005;7(3):249-62
pubmed: 16156383
Ther Adv Chronic Dis. 2016 May;7(3):160-9
pubmed: 27347363
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
J Clin Psychiatry. 2021 Jun 15;82(4):
pubmed: 34133089
J Affect Disord. 2017 Jun;215:299-313
pubmed: 28364701
Expert Opin Drug Discov. 2019 Jan;14(1):81-89
pubmed: 30457395
CNS Spectr. 2021 Oct 18;:1-26
pubmed: 34657638
J Clin Psychiatry. 2017 Jan;78(1):115-121
pubmed: 27780334
Am J Psychiatry. 2016 Feb 1;173(2):174-83
pubmed: 26552940